vs
Side-by-side financial comparison of AtriCure, Inc. (ATRC) and Caesarstone Ltd. (CSTE). Click either name above to swap in a different company.
AtriCure, Inc. is the larger business by last-quarter revenue ($141.2M vs $94.4M, roughly 1.5× Caesarstone Ltd.). AtriCure, Inc. runs the higher net margin — 0.1% vs -93.1%, a 93.2% gap on every dollar of revenue. Over the past eight quarters, AtriCure, Inc.'s revenue compounded faster (10.2% CAGR vs -57.8%).
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...
ATRC vs CSTE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.2M | $94.4M |
| Net Profit | $108.0K | $-87.9M |
| Gross Margin | 77.4% | 15.5% |
| Operating Margin | 23.0% | -87.2% |
| Net Margin | 0.1% | -93.1% |
| Revenue YoY | 14.3% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $-2.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $94.4M | ||
| Q3 25 | $134.3M | $345.4M | ||
| Q2 25 | $136.1M | $237.7M | ||
| Q1 25 | $123.6M | — | ||
| Q4 24 | $124.3M | — | ||
| Q3 24 | $115.9M | $436.7M | ||
| Q2 24 | $116.3M | $294.3M |
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $-87.9M | ||
| Q3 25 | $-267.0K | $-18.5M | ||
| Q2 25 | $-6.2M | $-14.3M | ||
| Q1 25 | $-6.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.9M | $-57.4M | ||
| Q2 24 | $-8.0M | $-56.6M |
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | 15.5% | ||
| Q3 25 | 75.5% | 22.5% | ||
| Q2 25 | 74.5% | 23.7% | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | 15.7% | ||
| Q2 24 | 74.7% | 14.1% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | -87.2% | ||
| Q3 25 | 0.2% | -5.5% | ||
| Q2 25 | -4.5% | -6.2% | ||
| Q1 25 | -4.8% | — | ||
| Q4 24 | -11.7% | — | ||
| Q3 24 | -6.4% | -12.6% | ||
| Q2 24 | -6.2% | -18.0% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | -93.1% | ||
| Q3 25 | -0.2% | -5.4% | ||
| Q2 25 | -4.5% | -6.0% | ||
| Q1 25 | -5.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.8% | -13.1% | ||
| Q2 24 | -6.9% | -19.2% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $-2.55 | ||
| Q3 25 | $-0.01 | $-0.54 | ||
| Q2 25 | $-0.13 | $-0.41 | ||
| Q1 25 | $-0.14 | — | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.17 | $-1.67 | ||
| Q2 24 | $-0.17 | $-1.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.2M | $58.4M |
| Total DebtLower is stronger | $61.0M | — |
| Stockholders' EquityBook value | $491.7M | $139.2M |
| Total Assets | $644.0M | $398.4M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $58.4M | ||
| Q3 25 | $147.9M | — | ||
| Q2 25 | $117.8M | — | ||
| Q1 25 | $99.9M | — | ||
| Q4 24 | $122.7M | — | ||
| Q3 24 | $130.3M | — | ||
| Q2 24 | $114.0M | — |
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $139.2M | ||
| Q3 25 | $476.5M | $271.6M | ||
| Q2 25 | $464.5M | $271.6M | ||
| Q1 25 | $454.6M | — | ||
| Q4 24 | $461.0M | — | ||
| Q3 24 | $465.0M | $315.1M | ||
| Q2 24 | $462.1M | $315.1M |
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $398.4M | ||
| Q3 25 | $635.4M | $549.0M | ||
| Q2 25 | $608.8M | $549.0M | ||
| Q1 25 | $591.6M | — | ||
| Q4 24 | $609.3M | — | ||
| Q3 24 | $615.1M | $579.9M | ||
| Q2 24 | $597.3M | $579.9M |
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-38.0M |
| Free Cash FlowOCF − Capex | — | $-47.1M |
| FCF MarginFCF / Revenue | — | -49.8% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $38.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $-38.0M | ||
| Q3 25 | $26.7M | $35.0M | ||
| Q2 25 | $21.6M | $18.7M | ||
| Q1 25 | $-11.0M | — | ||
| Q4 24 | $5.8M | — | ||
| Q3 24 | $20.0M | $53.3M | ||
| Q2 24 | $7.4M | $25.1M |
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $-47.1M | ||
| Q3 25 | $24.1M | $26.7M | ||
| Q2 25 | $19.0M | $14.3M | ||
| Q1 25 | $-13.2M | — | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $16.4M | $44.6M | ||
| Q2 24 | $5.0M | $20.7M |
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | -49.8% | ||
| Q3 25 | 18.0% | 7.7% | ||
| Q2 25 | 13.9% | 6.0% | ||
| Q1 25 | -10.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 14.1% | 10.2% | ||
| Q2 24 | 4.3% | 7.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 9.6% | ||
| Q3 25 | 1.9% | 2.4% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 3.1% | 2.0% | ||
| Q2 24 | 2.1% | 1.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
CSTE
| America's | $53.0M | 56% |
| USA | $41.4M | 44% |
